These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 9284426

  • 1. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
    Andersson OK, Neldam S.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S63-4. PubMed ID: 9331011
    [No Abstract] [Full Text] [Related]

  • 4. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
    [Abstract] [Full Text] [Related]

  • 5. [The usefulness of a new class antihypertensive drug, angiotensin II receptor antagonist, for essential hypertension].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 1999 May; 57(5):1141-7. PubMed ID: 10361448
    [Abstract] [Full Text] [Related]

  • 6. [ACE inhibitors or AT1 receptor antagonists?].
    Riegger GA.
    Dtsch Med Wochenschr; 1999 Sep 24; 124 Suppl 2():S37-9. PubMed ID: 10535045
    [No Abstract] [Full Text] [Related]

  • 7. Role of the renin-angiotensin system in hypertension in the elderly.
    Nagano M, Higaki J, Mikami H, Ogihara T.
    Blood Press Suppl; 1994 Sep 24; 5():130-3. PubMed ID: 7889195
    [Abstract] [Full Text] [Related]

  • 8. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM.
    Int J Clin Pract; 2006 Apr 24; 60(4):391-8. PubMed ID: 16620350
    [Abstract] [Full Text] [Related]

  • 9. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, Kiowski W, Marks DS, Alegria E, Dukát A, Lenz K, Arens HA.
    Am Heart J; 2003 Mar 24; 145(3):E14. PubMed ID: 12660683
    [Abstract] [Full Text] [Related]

  • 10. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec 24; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH, Investigators.
    Clin Ther; 2012 Mar 24; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [Abstract] [Full Text] [Related]

  • 12. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
    Franke H.
    J Hum Hypertens; 1997 Sep 24; 11 Suppl 2():S61-2. PubMed ID: 9331010
    [No Abstract] [Full Text] [Related]

  • 13. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.
    Gradman AH, Lewin A, Bowling BT, Tonkon M, Deedwania PC, Kezer AE, Hardison JD, Cushing DJ, Michelson EL.
    Heart Dis; 1999 Sep 24; 1(2):52-7. PubMed ID: 11720604
    [Abstract] [Full Text] [Related]

  • 14. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
    Ruilope L.
    Blood Press Suppl; 2000 Sep 24; 1():31-5. PubMed ID: 11059634
    [Abstract] [Full Text] [Related]

  • 15. [Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
    Winkler G, Jermendy G, Matos L.
    Orv Hetil; 2003 Sep 21; 144(38):1861-7. PubMed ID: 14596024
    [Abstract] [Full Text] [Related]

  • 16. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000 Sep 21; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 17. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S, Stirling AL.
    Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259
    [Abstract] [Full Text] [Related]

  • 18. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P.
    Blood Press Suppl; 2000 Apr 15; 1():23-6. PubMed ID: 11059632
    [Abstract] [Full Text] [Related]

  • 19. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 20. Reducing cardiovascular morbidity and mortality in the elderly.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep 15; 1():40-3. PubMed ID: 11059636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.